Nevertheless, outside patients with renal cell carcinoma, refractory mantle cell lymphoma and ER-positive/HER2-negative breast cancer when combined with hormone therapy, the antitumour activity of the first generation of mTOR inhibitors (rapalogs) has fallen short of expectations. Here, ERBB2 is linked to breast carcinoma.